Donatella Del Bufalo

List of Publications by Year
in descending order

128 papers	4,925 citations	71102 41 h-index	110387 64 g-index
130 all docs	130 docs citations	130 times ranked	7476 citing authors

#	Article	IF	Citations
1	Editorial on Special Issue â€œAdvances and Novel Treatment Options in Metastatic Melanomaâ€. Cancers, 2022, 14, 707.	3.7	2
2	Negative Modulation of the Angiogenic Cascade Induced by Allosteric Kinesin Eg5 Inhibitors in a Gastric Adenocarcinoma In Vitro Model. Molecules, 2022, 27, 957.	3.8	10
3	Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules. Theranostics, 2022, 12, 2427-2444.	10.0	12
4	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 148.	8.6	10
5	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. European Journal of Medicinal Chemistry, 2022, 237, 114410.	5.5	15
6	Bcl-xL: A Focus on Melanoma Pathobiology. International Journal of Molecular Sciences, 2021, 22, 2777.	4.1	17
7	SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia. Journal of Experimental and Clinical Cancer Research, 2021, 40, 131.	8.6	5
8	Antitumor effect of Melaleuca alternifolia essential oil and its main component terpinen-4-ol in combination with target therapy in melanoma models. Cell Death Discovery, 2021, 7, 127.	4.7	24
9	Hypoxia-dependent drivers of melanoma progression. Journal of Experimental and Clinical Cancer Research, 2021, 40, 159.	8.6	45
10	New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy. Drug Discovery Today, 2021, 26, 1126-1135.	6.4	15
11	The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells. Cells, 2021, 10, 1877.	4.1	8
12	First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. Journal of Medicinal Chemistry, 2021, 64, 17031-17050.	6.4	7
13	Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma. Cancers, 2020, 12, 2650.	3.7	19
14	The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells. International Journal of Molecular Sciences, 2020, 21, 8433.	4.1	9
15	Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells, 2020, 9, 1287.	4.1	84
16	Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells. Journal of Experimental and Clinical Cancer Research, 2020, 39, 103.	8.6	5
17	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. ACS Medicinal Chemistry Letters, 2020, 11, 977-983.	2.8	49
18	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers, 2020, 12, 447.	3.7	8

#	Article	IF	Citations
19	microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis, 2020, 9, 22.	4.9	30
20	Targeting hypoxia in tumor: a new promising therapeutic strategy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 8.	8.6	38
21	Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. , 2020, 8, e000489.		30
22	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRASâ€“Dependent Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 5612-5625.	0.9	11
23	Abstract 768: miR-378a-5p acts as a positive regulator of melanoma progression. , 2019, , .		0
24	Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis, 2018, 7, 20.	4.9	20
25	A double point mutation at residues Ile14 and Val15 of Bclâ€2 uncovers a role for the BH4 domain in both protein stability and function. FEBS Journal, 2018, 285, 127-145.	4.7	16
26	Small molecules targeted to the microtubuleâ€“Hec1 interaction inhibit cancer cell growth through microtubule stabilization. Oncogene, 2018, 37, 231-240.	5.9	18
27	Interleukin 8 mediates bclâ€xLâ€induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. International Journal of Cancer, 2018, 142, 584-596.	5.1	51
28	Emerging Role of Histone Acetyltransferase in Stem Cells and Cancer. Stem Cells International, 2018, 2018, 1-11.	2.5	43
29	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. Journal of Experimental and Clinical Cancer Research, 2018, 37, 278.	8.6	19
30	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease, 2018, 9, 996.	6.3	75
31	HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene, 2018, 37, 5926-5938.	5.9	24
32	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	8.6	27
33	Abstract 3699: Histone deacetylase inhibitor ITF2357 induces apoptosis and increases doxorubicin cytotoxicity in preclinical models of human sarcoma. , 2018, , .		0
34	Abstract 5: The histone acetyltransferase inhibitor CPTH6 impairs tumor angiogenesis acting on both endothelial and cancer cells. , 2018, , .		0
35	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	3.3	44
36	Metabolite profiling of ascidian Styela plicata using LCâ€“MS with multivariate statistical analysis and their antitumor activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 614-623.	5.2	17

#	Article	IF	Citations
37	Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain. Carcinogenesis, 2017, 38, 579-587.	2.8	39
38	Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene, 2017, 36, 4573-4584.	5.9	123
39	BCL-XL overexpression promotes tumor progression-associated properties. Cell Death and Disease, 2017, 8, 3216.	6.3	76
40	Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. ELife, 2017, 6, .	6.0	47
41	Abstract 933: Bcl-xL overexpression promotes tumor aggressiveness. , 2017, , .		0
42	miR-211 and MITF modulation by Bcl-2 protein in melanoma cells. Molecular Carcinogenesis, 2016, 55, 2304-2312.	2.7	23
43	NAADP-Dependent Ca2+ Signaling Controls Melanoma Progression, Metastatic Dissemination and Neoangiogenesis. Scientific Reports, 2016, 6, 18925.	3.3	35
44	Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein. Cell Death and Disease, 2016, 7, e2090-e2090.	6.3	11
45	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 1471-1491.	6.4	60
46	The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. Oncotarget, 2016, 7, 55789-55810.	1.8	81
47	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget, 2016, 7, 11332-11348.	1.8	49
48	Abstract 4721: Enhancement of doxorubicin cytotoxicity by histone deacetylase inhibition in human sarcoma cells. , 2016, , .		0
49	3309 A novel function of Bcl-2 protein: miR-211 regulation in melanoma cells. European Journal of Cancer, 2015, 51, S667.	2.8	0
50	<scp>TLR</scp>3 engagement induces <scp>IRF</scp>â€3â€dependent apoptosis in androgenâ€sensitive prostate cancer cells and inhibits tumour growth in vivo. Journal of Cellular and Molecular Medicine, 2015, 19, 327-339.	3.6	44
51	N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochoreâ€“microtubule dynamics. Oncogene, 2015, 34, 3325-3335.	5.9	9
52	PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. Oncotarget, 2015, 6, 15008-15021.	1.8	32
53	Abstract 2324: The histone acetyltransferase inhibitor CPTH6 selectively targets lung cancer stem-like cells. , 2015, , .		0
54	Kinetochore-microtube attachments in cancer therapy. Oncoscience, 2015, 2, 902-903.	2.2	0

#	Article	IF	Citations
55	Synergistic Growth Inhibitory Activity of Combined Mek/Mtor Pathway Blockade in Pten-Null Cancers. Annals of Oncology, 2014, 25, iv548.	1.2	0
56	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Molecular Cancer, 2014, 13, 230.	19.2	51
57	VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2â€“dependent Ca ²⁺ signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4706-15.	7.1	138
58	241: Bcl-xL protein overexpression enhances tumor progression of human melanoma cells in zebrafish xenograft model: involvement of interleukin 8. European Journal of Cancer, 2014, 50, S56.	2.8	0
59	822: The histone acetyltransferases inhibitor CPTH6 preferentially inhibits proliferation of patient-derived lung cancer stem cells in vitro and in vivo. European Journal of Cancer, 2014, 50, S199.	2.8	0
60	284: Evidence of a correlation between bcl-2 protein and miR-211 expression in melanoma cell lines. European Journal of Cancer, 2014, 50, S67.	2.8	0
61	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6259-6265.	6.4	102
62	Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors. Molecular Cancer Research, 2014, 12, 878-889.	3.4	18
63	Abstract 1684: Histone deacetylase inhibition enhances Pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer models. , 2014, , .		0
64	Abstract 77: bcl-xL protein overexpression enhances tumor progression of human melanoma cells in zebrafish xenograft model: Involvement of CXCL8 chemokine. , 2014, , .		0
65	Abstract 2618: PTEN loss as a putative biomarker of synergistic growth inhibitory activity of combined MEK/ERK and PI3K/mTOR pathway blockade. , 2014, , .		0
66	tertâ€Butylcarbamateâ€Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. ChemMedChem, 2013, 8, 800-811.	3.2	16
67	Removal of the BH4 Domain from Bcl-2 Protein Triggers an Autophagic Process that Impairs Tumor Growth. Neoplasia, 2013, 15, 315-IN37.	5.3	29
68	BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. Carcinogenesis, 2013, 34, 2558-2567.	2.8	23
69	Papillary Carcinoma of the Thyroid: High Expression of COX-2 and Low Expression of KAI-1/CD82 Are Associated with Increased Tumor Invasiveness. Thyroid, 2013, 23, 1127-1137.	4.5	14
70	The thiazole derivative CPTH6 impairs autophagy. Cell Death and Disease, 2013, 4, e524-e524.	6.3	28
71	CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells. Clinical Cancer Research, 2012, 18, 475-486.	7.0	47
72	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for â€œverticalâ€•and â€œlateralâ€•combination strategies. Journal of Molecular Medicine, 2012, 90, 1133-1144.	3.9	35

#	Article	IF	Citations
73	Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochemical Pharmacology, 2012, 84, 598-611.	4.4	26
74	LMNA Knock-Down Affects Differentiation and Progression of Human Neuroblastoma Cells. PLoS ONE, 2012, 7, e45513.	2.5	40
75	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine, 2012, 90, 667-679.	3.9	54
76	Abstract LB-82: Modulation of autophagic flux by CPTH6, a Gcn5/pCAF histone acetyltransferase inhibitor with antitumoral activity. , 2012, , .		0
77	Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. British Journal of Cancer, 2011, 104, 769-780.	6.4	52
78	Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death and Differentiation, 2011, 18, 1024-1035.	11.2	53
79	Lost in translation: bridging the gap between cancer research and effective therapies. Cell Death and Differentiation, 2011, 18, 1082-1084.	11.2	1
80	Abstract 16: Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. , 2011, , .		0
81	Bcl-2 Regulates HIF-1Î± Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90. PLoS ONE, 2010, 5, e11772.	2.5	72
82	Toll-like Receptor 3 Regulates Angiogenesis and Apoptosis in Prostate Cancer Cell Lines through Hypoxia-Inducible Factor 1Î±. Neoplasia, 2010, 12, 539-549.	5.3	85
83	Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression.. Journal of Clinical Oncology, 2010, 28, 8574-8574.	1.6	0
84	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nature Structural and Molecular Biology, 2009, 16, 1086-1093.	8.2	182
85	Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. European Journal of Cancer, 2009, 45, 2618-2627.	2.8	121
86	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. Neoplasia, 2009, 11, 720-W6.	5.3	87
87	Involvement of nuclear factorâ€kappa B in bclâ€xLâ€induced interleukin 8 expression in glioblastoma. Journal of Neurochemistry, 2008, 107, 871-882.	3.9	41
88	Induction of Apoptosis in Human Cancer Cells by Candidaspongiolide, a Novel Sponge Polyketide. Journal of the National Cancer Institute, 2008, 100, 1233-1246.	6.3	39
89	Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression. Molecular Cancer Research, 2007, 5, 761-771.	3.4	41
90	Involvement of RB gene family in tumor angiogenesis. Oncogene, 2006, 25, 5326-5332.	5.9	47

#	Article	IF	Citations
91	Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. Cancer Research, 2006, 66, 5549-5554.	0.9	314
92	Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death and Differentiation, 2005, 12, 1429-1438.	11.2	124
93	Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. Journal of Cellular Physiology, 2005, 205, 414-421.	4.1	69
94	Involvement of PI3K and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth Factor Expression in Melanoma Cells. Molecular Biology of the Cell, 2005, 16, 4153-4162.	2.1	88
95	Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. European Journal of Cancer, 2005, 41, 1213-1222.	2.8	23
96	Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Geneâ€“Amplified Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 7747-7756.	7.0	50
97	bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation. Journal of Biological Chemistry, 2004, 279, 6737-6745.	3.4	60
98	Lonidamine Causes Inhibition of Angiogenesis-Related Endothelial Cell Functions. Neoplasia, 2004, 6, 513-522.	5.3	29
99	Crosstalk between VEGF and Bcl-2 in Tumor Progression and Angiogenesis. , 2004, , 26-39.		0
100	Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene, 2003, 22, 8441-8447.	5.9	59
101	Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells. Molecular Pharmacology, 2003, 63, 632-638.	2.3	27
102	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Molecular Pharmacology, 2002, 61, 524-532.	2.3	132
103	Bclâ€2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIFâ€1mediated transcriptional activity. FASEB Journal, 2002, 16, 1453-1455.	0.5	117
104	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clinical Science, 2002, 103, 302S-305S.	4.3	24
105	Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. European Journal of Cancer, 2002, 38, 2455-2462.	2.8	32
106	ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. International Journal of Cancer, 2002, 98, 463-469.	5.1	87
107	Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. Oncogene, 2002, 21, 3011-3019.	5.9	29
108	C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells. Molecular Pharmacology, 2001, 60, 174-182.	2.3	82

#	Article	IF	Citations
109	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. Journal of Cellular Biochemistry, 2001, 83, 473-483.	2.6	14
110	relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. British Journal of Cancer, 2001, 85, 1914-1921.	6.4	51
111	bcl-2 over-expression enhances NF-?B activity and induces mmp-9 transcription in human MCF7ADR breast-cancer cells. , 2000, 86, 188-196.		89
112	Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. International Journal of Cancer, 2000, 87, 615-628.	5.1	70
113	Bclâ€2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression andin vivoangiogenesis in a breast carcinoma line. FASEB Journal, 2000, 14, 652-660.	0.5	115
114	Intracellular Pâ€glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. International Journal of Cancer, 2000, 87, 615-628.	5.1	3
115	bcl-2 over-expression enhances NF-ÎºB activity and induces mmp-9 transcription in human MCF7ADR breast-cancer cells. International Journal of Cancer, 2000, 86, 188.	5.1	1
116	Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Therapy, 1999, 6, 1064-1072.	4.5	31
117	bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant mcf7 cells. , 1999, 82, 125-130.		31
118	N-methylformamide induces changes on adhesive properties and lung-colonizing potential of M14 melanoma cells. British Journal of Cancer, 1998, 77, 210-215.	6.4	4
119	Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. , 1998, 75, 885-893.		57
120	Bclâ€2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB Journal, 1997, 11, 947-953.	0.5	126
121	Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. British Journal of Cancer, 1996, 74, 387-393.	6.4	22
122	Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.. Journal of Clinical Investigation, 1996, 98, 1165-1173.	8.2	47
123	Pre-Treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. International Journal of Cancer, 1994, 58, 95-101.	5.1	15
124	N-methylformamide as a potential therapeutic approach in colon cancer. Diseases of the Colon and Rectum, 1994, 37, S133-S137.	1.3	7
125	Therapeutic potential of differentiating agents in colon cancer treatment. Journal of Surgical Oncology, 1991, 48, 14-15.	1.7	0
126	N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice. Clinical and Experimental Metastasis, 1990, 8, 153-163.	3.3	7

#	Article	IF	Citations
127	Bcl-2-like protein-10 increases aggressive features of melanoma cells. Exploration of Targeted Anti-tumor Therapy, 0, , 11-26.	0.8	5
128	Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition. Frontiers in Oncology, 0, 12, .	2.8	2